Lipid Disorders - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：57頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Lipid Disorders - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Lipid Disorders - Pipeline Review, H1 2014’, provides an overview of the Lipid Disorders’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Lipid Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipid Disorders and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Lipid Disorders
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Lipid Disorders and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Lipid Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lipid Disorders pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lipid Disorders
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lipid Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Lipid Disorders - Pipeline Review, H1 2014’, provides an overview of the Lipid Disorders’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Lipid Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipid Disorders and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Lipid Disorders
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Lipid Disorders and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Lipid Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lipid Disorders pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lipid Disorders
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lipid Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lipid Disorders Overview 6
Therapeutics Development 7
Pipeline Products for Lipid Disorders - Overview 7
Pipeline Products for Lipid Disorders - Comparative Analysis 8
Lipid Disorders - Therapeutics under Development by Companies 9
Lipid Disorders - Therapeutics under Investigation by Universities/Institutes 11
Lipid Disorders - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Lipid Disorders - Products under Development by Companies 14
Lipid Disorders - Products under Investigation by Universities/Institutes 15
Lipid Disorders - Companies Involved in Therapeutics Development 16
Catabasis Pharmaceuticals, Inc. 16
Kythera Biopharmaceuticals, Inc. 17
Esperion Therapeutics, Inc. 18
Connexios Life Sciences Pvt. Ltd. 19
Lipid Disorders - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
deoxycholic acid - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Recombinant Protein for Atherosclerosis and Lipid Disorders - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CNX-013-B2 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
4-WF - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CAT-2054 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules for Lipid Storage in Rare Disease - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Lipid Disorders - Recent Pipeline Updates 37
Lipid Disorders - Dormant Projects 43
Lipid Disorders - Product Development Milestones 44
Featured News & Press Releases 44
Oct 07, 2013: KYTHERA Announces Additional Positive Efficacy and Patient Satisfaction Data From ATX-101 Phase III Trials for the Reduction of Submental Fat 44
Sep 16, 2013: KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Results for the Reduction of Submental Fat 45
Aug 06, 2013: Piramal receives IND approval for P7435, its novel DGAT1 inhibitor for treatment of Lipid Disorders and Diabetes 47
Apr 13, 2013: Kythera Biopharma Presents Positive MRI Results From Phase IIb Study Of ATX-101 For Reduction Of Submental Fat At ASAPS 2013 48
Apr 06, 2013: Kythera Biopharma Announces Positive Interim Results From Phase IIIb Study Of ATX-101 At 11th Anti-Aging Medicine World Congress 49
Apr 05, 2013: Kythera Biopharma Enters Into Commercial Development And Supply Agreement With Cambridge Major Labs 50
Apr 04, 2013: Bayer’s ATX-101 Significantly And Sustainably Reduces Unwanted Fat Under Chin 51
Mar 01, 2013: Kythera Biopharma Announces Positive Interim Results From Phase IIIb Study Of ATX-101 In Reduction Of Unwanted Submental Fat 52
Mar 01, 2013: Kythera Biopharma To Present New Data On ATX-101 At 2013 American Academy Of Dermatology Annual Meeting 53
Feb 01, 2013: Bayer Presents Results From Two Pivotal European Phase-III Studies Of ATX-101 At IMCAS 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57
List of Tables
Number of Products under Development for Lipid Disorders, H1 2014 7
Number of Products under Development for Lipid Disorders - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Lipid Disorders - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 16
Lipid Disorders - Pipeline by Kythera Biopharmaceuticals, Inc., H1 2014 17
Lipid Disorders - Pipeline by Esperion Therapeutics, Inc., H1 2014 18
Lipid Disorders - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Lipid Disorders Therapeutics - Recent Pipeline Updates, H1 2014 37
Lipid Disorders - Dormant Projects, H1 2014 43
List of Figures
Number of Products under Development for Lipid Disorders, H1 2014 7
Number of Products under Development for Lipid Disorders - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lipid Disorders Overview 6
Therapeutics Development 7
Pipeline Products for Lipid Disorders - Overview 7
Pipeline Products for Lipid Disorders - Comparative Analysis 8
Lipid Disorders - Therapeutics under Development by Companies 9
Lipid Disorders - Therapeutics under Investigation by Universities/Institutes 11
Lipid Disorders - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Lipid Disorders - Products under Development by Companies 14
Lipid Disorders - Products under Investigation by Universities/Institutes 15
Lipid Disorders - Companies Involved in Therapeutics Development 16
Catabasis Pharmaceuticals, Inc. 16
Kythera Biopharmaceuticals, Inc. 17
Esperion Therapeutics, Inc. 18
Connexios Life Sciences Pvt. Ltd. 19
Lipid Disorders - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
deoxycholic acid - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Recombinant Protein for Atherosclerosis and Lipid Disorders - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CNX-013-B2 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
4-WF - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CAT-2054 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules for Lipid Storage in Rare Disease - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Lipid Disorders - Recent Pipeline Updates 37
Lipid Disorders - Dormant Projects 43
Lipid Disorders - Product Development Milestones 44
Featured News & Press Releases 44
Oct 07, 2013: KYTHERA Announces Additional Positive Efficacy and Patient Satisfaction Data From ATX-101 Phase III Trials for the Reduction of Submental Fat 44
Sep 16, 2013: KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Results for the Reduction of Submental Fat 45
Aug 06, 2013: Piramal receives IND approval for P7435, its novel DGAT1 inhibitor for treatment of Lipid Disorders and Diabetes 47
Apr 13, 2013: Kythera Biopharma Presents Positive MRI Results From Phase IIb Study Of ATX-101 For Reduction Of Submental Fat At ASAPS 2013 48
Apr 06, 2013: Kythera Biopharma Announces Positive Interim Results From Phase IIIb Study Of ATX-101 At 11th Anti-Aging Medicine World Congress 49
Apr 05, 2013: Kythera Biopharma Enters Into Commercial Development And Supply Agreement With Cambridge Major Labs 50
Apr 04, 2013: Bayer’s ATX-101 Significantly And Sustainably Reduces Unwanted Fat Under Chin 51
Mar 01, 2013: Kythera Biopharma Announces Positive Interim Results From Phase IIIb Study Of ATX-101 In Reduction Of Unwanted Submental Fat 52
Mar 01, 2013: Kythera Biopharma To Present New Data On ATX-101 At 2013 American Academy Of Dermatology Annual Meeting 53
Feb 01, 2013: Bayer Presents Results From Two Pivotal European Phase-III Studies Of ATX-101 At IMCAS 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57
List of Tables
Number of Products under Development for Lipid Disorders, H1 2014 7
Number of Products under Development for Lipid Disorders - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Lipid Disorders - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 16
Lipid Disorders - Pipeline by Kythera Biopharmaceuticals, Inc., H1 2014 17
Lipid Disorders - Pipeline by Esperion Therapeutics, Inc., H1 2014 18
Lipid Disorders - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Lipid Disorders Therapeutics - Recent Pipeline Updates, H1 2014 37
Lipid Disorders - Dormant Projects, H1 2014 43
List of Figures
Number of Products under Development for Lipid Disorders, H1 2014 7
Number of Products under Development for Lipid Disorders - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28
